(Press-News.org)
Rare diseases, which affect 30 million people across Europe, are entering a new phase in diagnosis and treatment. Key initiatives include the creation of a European registry dedicated to rare diseases and the launch of Europe’s first postgraduate specialization program with academic credit recognition (a second-level master’s degree). This joint degree, offered in collaboration with various European universities, aims to train professionals with expertise in rare disease research.
The team is coordinated by Professor Wanda Lattanzi, Associate Professor of Cellular and Applied Biology at the Department of Life Sciences and Public Health at the Catholic University and medical geneticist consultant at the Pediatric Neurosurgery Unit of Policlinico Gemelli. The team includes Professor Ornella Parolini, Full Professor of Cellular and Applied Biology and Director of the Research Biobank, Professor Alessandro Arcovito, Associate Professor of Biochemistry, Professor Giuseppe Zampino, Associate Professor of General and Specialized Pediatrics and Head of the Rare Diseases Center, researcher Dr. Lorena Di Pietro, and Laura Motta, the administrative officer from the Research Office. Plus a strong support by the teams from the Academic Planning, Educational Offer, and International Office.
ERDERA, funded with €380 million under Horizon IHI, is a major 7-year project that involves 178 institutions across 37 countries (26 EU member states, 8 associated countries, and 3 non-EU countries). The consortium includes universities, clinical centers, public administrations, research organizations, patient associations, research infrastructures, and industry partners.
Professor Lattanzi serves as the scientific coordinator for the Università Cattolica, leading efforts in “training and education” to develop academic programs in collaboration with other European universities. These programs aim to train new professionals in rare disease research.
Rare Diseases: A Global Challenge
Globally, up to 5% of the population is affected by rare diseases. In Italy alone, approximately 2 million people suffer from rare diseases, 70% of whom are pediatric patients, according to Orphanet Italia. While around 10,000 rare diseases are currently known and diagnosed, the actual number continues to rise as research advances. Approximately 72% of rare diseases have a genetic origin, while the remainder are linked to infections, allergies, environmental factors, or rare cancers.
About ERDERA
ERDERA was officially launched on September 1, 2024, and will be presented at a two-day event in Paris at INSERM. The alliance’s overarching goal is to improve the health and well-being of the 30 million Europeans affected by rare diseases. ERDERA aims to make Europe a global leader in rare disease research and innovation by enhancing prevention, diagnosis, and treatment strategies.
The program supports the European Union’s commitment to the United Nations 2030 Agenda for Sustainable Development Goals (SDG 3: Good Health and Well-being, and SDG 10: Reduced Inequalities). ERDERA will foster a multi-stakeholder research ecosystem, driving patient-centered research, sharing of health and research data, and promoting digital transformation in research and innovation.
One of ERDERA’s major objectives is to ensure that every willing rare disease patient can be identified and enrolled in suitable clinical trials. By promoting data generation and sharing, ERDERA aims to accelerate progress in understanding, diagnosing, preventing, and treating rare diseases.
Università Cattolica’s Role in ERDERA
The Università Cattolica is a key beneficiary of ERDERA, contributing to Work Package 20, which focuses on “education and training” initiatives. The overarching aim is to create a comprehensive education and training program for rare disease research professionals. The program will address the needs of the research community at all career stages and engage a broader multi-stakeholder group, including patients, healthcare providers, industry representatives, and governmental bodies.
Professor Lattanzi concludes:
“Europe currently lacks a professional profile specialized in rare diseases, with the capacity to manage the evolving tools and technologies in basic, translational, and clinical research. In addition to technical skills, these professionals must possess multidisciplinary expertise, enabling innovation and technology transfer, and strong communication abilities for scientific dissemination and patient engagement. Educational resources for rare disease research professionals remain fragmented across EU countries, resulting in inconsistent professional profiles. ERDERA aims to standardize training objectives and teaching methods across academic and research institutions, culminating in a formalized joint degree recognized by participating European universities.”
END
Embargoed for release: Monday, September 30, 11:00 AM ET
Key points:
There are no nationally required nutrition competencies within medical education in the U.S. In that context, researchers surveyed a professionally diverse panel of medical and nutrition experts to reach a consensus on proposed nutrition competencies for medical students and physician trainees, as well as recommendations for how to evaluate them.
The proposed competencies directly respond to Congress’ bipartisan resolution H. Res. 1118, which calls for “meaningful physician ...
Earlier this summer, members of the National Center for Supercomputing Applications traveled to Alaska as part of their continued work with the Permafrost Discovery Gateway, a project led by the Woodwell Climate Research Center using artificial intelligence (AI) and machine learning (ML) in tracking Arctic permafrost thaw.
NCSA’s Associate Director for Software Kenton McHenry and Research Software Engineer Todd Nicholson visited Fairbanks, Alaska along with 12 Google.org fellows to see first hand the melting permafrost and the impacts to those that live there.
“I have seen ...
Rockville, MD. (September 30, 2024) – The 2024 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by the National Foundation for Cancer Research (NFCR) and AIM-HI Accelerator Fund, will be held on October 18th at the National Press Club in Washington, DC.
This is the one event each year where key leaders from the entire cancer research and patient care ecosystem come together under one roof to share critical discoveries and ideas from all areas of cancer research, drug development, and patient care. This is where many innovative ...
About The Study: In an open-label trial in patients with heart failure with preserved ejection fraction with left ventricular ejection fraction of 60% or greater, mavacamten, a cardiac myosin inhibitor, was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in left ventricular ejection fraction observed.
Corresponding Authors: To contact the corresponding authors, email Sanjiv J. Shah, MD, (sanjiv.shah@northwestern.edu) and Scott ...
NEW YORK — The American Federation for Aging Research (AFAR) is pleased to announce the recipient of the 2024 Sagol Network GerOmic Award for Junior Faculty: Amy Vandiver, MD, PhD, Clinical Instructor Clinician-Investigator Track, University of California Los Angeles. Established in 2020, the Sagol Network GerOmic Award for Junior Faculty is a one- to two-year award given to junior faculty (MDs and PhDs) to conduct aging-related Omics (GerOmics) research.
Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, ...
WASHINGTON, September 30, 2024 — An accelerated course of radiation therapy does not increase complications for patients who undergo breast reconstruction following a mastectomy, new research shows. Findings of the large, phase III RT CHARM trial (Alliance A221505) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
While radiation therapy following mastectomy to remove breast cancer is known to improve survival rates for certain patients who are at higher risk of recurrence, RT CHARM is the first multi-institutional international study to show that a shorter course ...
WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
“We tested two contemporary, advanced forms of external ...
WASHINGTON, September 30, 2024 — People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival. Findings of the multi-institutional phase III trial, which also found that twice-daily radiation treatments offer greater survival benefits than once-daily treatment, will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
The ...
WASHINGTON, September 30, 2024 — Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%. De-intensified treatments involving a lower radiation dose and immunotherapy in place of chemotherapy did not perform as well as the more rigorous chemoradiation approach. Findings of the NRG Oncology HN005 trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual ...
(WASHINGTON – September 30, 2024) In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded well to treatment with few serious side effects, according to results published today in Blood Advances.
LBCL is a cancer affecting B lymphocytes, a type of white blood cell. It can progress rapidly and is fatal if untreated, although most forms of LBCL respond well to standard ...
